Weiguo Ye Sells 12,820 Shares of Gyre Therapeutics (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) COO Weiguo Ye sold 12,820 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $6.15, for a total transaction of $78,843.00. Following the sale, the chief operating officer directly owned 700,000 shares in the company, valued at approximately $4,305,000. This trade represents a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Weiguo Ye also recently made the following trade(s):

• On Wednesday, May 20th, Weiguo Ye sold 9,400 shares of Gyre Therapeutics stock. The shares were sold at an average price of $6.15, for a total transaction of $57,810.00.

Gyre Therapeutics Stock Down 1.9%

NASDAQ GYRE opened at $6.06 on Friday. The company has a market cap of $588.00 million, a PE ratio of -67.33 and a beta of 2.03. Gyre Therapeutics, Inc. has a 52 week low of $5.97 and a 52 week high of $11.61. The firm’s 50-day simple moving average is $7.24 and its two-hundred day simple moving average is $7.60.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings data on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The business had revenue of $37.20 million for the quarter, compared to analysts’ expectations of $36.30 million. Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. As a group, equities research analysts anticipate that Gyre Therapeutics, Inc. will post -0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on GYRE shares. Weiss Ratings downgraded shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Zacks Research downgraded shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Finally, Wall Street Zen downgraded shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $17.00.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue purchased a new stake in shares of Gyre Therapeutics in the third quarter worth about $38,000. Bank of America Corp DE increased its position in shares of Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after purchasing an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Gyre Therapeutics by 84.6% in the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after purchasing an additional 3,244 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Gyre Therapeutics in the fourth quarter worth approximately $77,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.